Anti-CTLA-4 antibodies enhance immune responses and suppress neoantigen expression by activating the binding of CD28 to B7 and that of T cell receptor to major histocompatibility complex molecules, resulting in tumor cell elimination (Hu et al., 2019). Here, CTLA4 is linked to neoplasm.